why choose us

First received: June 20, 2024

Clinical Trial: Comparison of Complarate® (Tocilizumab Biosimilar) and Actemra® in Patients With Rheumatoid Arthritis

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Rheumatoid Arthritis

Study Type: INTERVENTIONAL


Official Title: Double-blind Multicenter Randomized Study of the Effectiveness and Safety of Tocilizumab Biosimilar (Complarate®) and Actemra® in Parallel Groups in Patients With Rheumatoid Arthritis With Repeated In

Brief Summary: This is a randomized double-blind comparative parallel group study of the efficacy and safety of tocilizumab biosimilar Complarate® and Actemra® in the treatment of patients with rheumatoid arthritis with moderate to high disease activity.Participants received an intravenous dose of tocilizumab 8 mg/kg once 4 weeks.The time on study treatment was 24 weeks.

Read more